Antipsychotics for behavioural and psychological problems in elderly people with dementia: A systematic review of adverse events

Drugs and Aging

Volumn 22, Issue 10, 2005, Pages 845-858

  Van Iersel, Marianne B ^a   Zuidema, Sytse U ^a   Koopmans, Raymond T C M ^a   Verhey, Frans R J ^b   Rikkert, Marcel G M Olde ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE; HALOPERIDOL; LOXAPINE; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PLACEBO; QUETIAPINE; RISPERIDONE; RIVASTIGMINE; TIAPRIDE; TRAZODONE;

ALZHEIMER DISEASE; BEHAVIOR DISORDER; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; CONFIDENCE INTERVAL; DATA BASE; DEMENTIA; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; EMBASE; EXTRAPYRAMIDAL SYMPTOM; HUMAN; INVOLUNTARY MOVEMENT; MEDLINE; MENTAL DISEASE; META ANALYSIS; MIXED DEPRESSION AND DEMENTIA; MOTOR DYSFUNCTION; MULTIINFARCT DEMENTIA; PRIORITY JOURNAL; REVIEW; SOMNOLENCE; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW;

AGED; AGING; ANTIPSYCHOTIC AGENTS; BEHAVIOR; CLINICAL TRIALS; DATABASES, BIBLIOGRAPHIC; DATABASES, FACTUAL; DEMENTIA; HUMANS;

EID: 27544473086     PISSN: 1170229X     EISSN: 1170229X     Source Type: Journal    
DOI: 10.2165/00002512-200522100-00004     Document Type: Review

References (51)

1. Hope T, Keene J, Fairburn CG, et al. Natural history of behavioural changes and psychiatric symptoms in Alzheimer's disease: a longitudinal study. Br J Psychiatry 1999; 174: 39-44
2. Paulsen JS, Salmon DP, Thal LJ, et al. Incidence of and risk factors for hallucinations and delusions in patients with probable AD. Neurology 2000; 54 (10): 1965-71
3. Steele C, Rovner B, Chase GA, et al. Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease. Am J Psychiatry 1990; 147 (8): 1049-51
4. Neil W, Curran S, Wattis J. Antipsychotic prescribing in older people. Age Ageing 2003; 32 (5): 475-83
5. Lee PE, Gill SS, Freedman M, et al. Atypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia: systematic review. BMJ 2004; 329 (7457): 75-9
6. Tariot PN, Profenno LA, Ismail MS. Efficacy of atypical antipsychotics in elderly patients with dementia. J Clin Psychiatry 2004; 65 Suppl. 11: 11-5
7. Wooltorton E. Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials. CMAJ 2002; 167 (11): 1269-70
8. Wooltorton E. Olanzapine (Zyprexa): increased incidence of cerebrovascular events in dementia trials [letter]. CMAJ 2004; 170 (9): 1395
9. FDA safety warning about the use of risperidone in the treatment of dementia-related psychosis [online]. Available from URL: http://www.fda.gov/ medwatch/SAFETY/2003/safety03.htm#risper [Accessed 2004 Sep 25]
10. Medicines and Healthcare Products Regulatory Agency. UK government warning cerebrovascular adverse events caused by risperidone [online]. Available from URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/ safetymessages/risperidoneclinicaltrialdata_final.pdf. [Accessed 2004 Sep 25]
11. European Medicines Agency. EMEA urgent safety warning for use of Zyprexa in elderly patients with dementia [online]. Available from URL: http://www.emea.eu.int/humandocs/Humans/EPAR/Zyprexa/Zyprexa.htm. [Accessed 2004 Sep 25]
12. Herrmann N, Mamdani M, Lanctot KL. Atypical antipsychotics and risk of cerebrovascular accidents. Am J Psychiatry 2004; 161 (6): 1113-5
13. Gill SS, Rochon PA, Herrmann N, et al. Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study. BMJ 2005; 330 (7489): 445-50
14. McKeith I. Commentary. Int Psychogeriatr 2005; 17 (2): 22-9
15. Ballard C, Cream J. Drugs used to relieve behavioral symptoms in people with dementia or an unacceptable chemical cosh? Argument. Int Psychogeriatr 2005; 17 (2): 4-12
16. Duff G. Atypical antipsychotic drugs and stroke: message from Professor Gordon Duff, Chairman, Committee on Safety of Medicines (CEM/CMO/2004/1) [online]. Available from URL: http://www.mca.gov.uk/aboutagency/regframework/ csm/csmhome.htm. [Accessed 2005 Apr 25]
17. Kuehn BM. FDA warns antipsychotic drugs may be risky for elderly [letter]. JAMA 2005; 293: 2462
18. Mowat D, Fowlie D, MacEwan T. CSM warning on atypical psychotics and stroke may be detrimental for dementia [letter]. BMJ 2004; 328 (7450): 1262
19. Shah A, Suh GH. A case for judicious use of risperidone and olanzapine in behavioral and psychological symptoms of dementia (BPSD): favour. Int Psychogeriatr 2005; 17 (2): 12-22
20. van Iersel M, Koopmans R, Zuidema S, et al. Do not use 'BPSD' if you want to be cited. Int J Geriatr Psychiatry 2004; 19 (8): 803-4
21. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34 (7): 939-44
22. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-III-R. 3rd ed., rev. Washington, DC: American Psychiatric Association, 1987
23. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-IV. Washington, DC: American Psychiatric Association, 1994
24. Roman GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993; 43 (2): 250-60
25. van Tulder MW, Assendelft WJ, Koes BW, et al. Method guidelines for systematic reviews in the Cochrane Collaboration Back Review Group for Spinal Disorders. Spine 1997; 22 (20): 2323-30
26. Ioannidis JP, Evans SJ, Gotzsche PC, et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med 2004; 141 (10): 781-8
27. Moher D, Schulz KF, Altman D. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 2001; 285 (15): 1987-91
28. Altman DG. Confidence intervals for the number needed to treat. BMJ 1998 Nov 7; 317 (7168): 1309-12
29. Allain H, Dautzenberg PH, Maurer K, et al. Double blind study of tiapride versus haloperidol and placebo in agitation and aggressiveness in elderly patients with cognitive impairment. Psychopharmacology (Berl) 2000; 148 (4): 361-6
30. Auchus AP, Bissey-Black C. Pilot study of haloperidol, fluoxetine, and placebo for agitation in Alzheimer's disease. J Neuropsychiatry Clin Neurosci 1997; 9 (4): 591-3
31. Brodaty H, Ames D, Snowdon J, et al. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry 2003; 64 (2): 134-43
32. Carlyle W, Ancill RJ, Sheldon L. Aggression in the demented patient: a double-blind study of loxapine versus haloperidol. Int Clin Psychopharmacol 1993; 8 (2): 103-8
33. De Deyn PP, Rabheru K, Rasmussen A, et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology 1999 Sep 22; 53 (5): 946-55
34. De Deyn PP, Carrasco MM, Deberdt W, et al. Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease. Int J Geriatr Psychiatry 2004; 19 (2): 115-26
35. Devanand DP, Marder K, Michaels KS, et al. A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease. Am J Psychiatry 1998; 155 (11): 1512-20
36. Katz IR, Jeste DV, Mintzer JE, et al. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. J Clin Psychiatry 1999; 60 (2): 107-15
37. Pollock BG, Mulsant BH, Rosen J, et al. Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. Am J Psychiatry 2002; 159 (3): 460-5
38. Street JS, Clark WS, Gannon KS, et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Arch Gen Psychiatry 2000; 57 (10): 968-76
39. Teri L, Logsdon RG, Peskind E, et al. Treatment of agitation in AD: a randomized, placebo-controlled clinical trial. Neurology 2000 Nov 14; 55 (9): 1271-8
40. Ballard C, Margallo-Lana M, Juszczak E, et al. Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial. BMJ 2005; 330 (7496): 874-8
41. Kindermann SS, Dolder CR, Bailey A, et al. Pharmacological treatment of psychosis and agitation in elderly patients with dementia: four decades of experience. Drugs Aging 2002; 19 (4): 257-76
42. Papanikolaou PN, Ioannidis JP. Availability of large-scale evidence on specific harms from systematic reviews of randomized trials. Am J Med 2004; 117 (8): 582-9
43. Nebeker JR, Barach P, Samore MH. Clarifying adverse drug events: a clinician's guide to terminology, documentation, and reporting. Ann Intern Med 2004; 140 (10): 795-801
44. Ioannidis JP, Lau J. Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. JAMA 2001; 285 (4): 437-43
45. Krzyzanowska MK, Pintilie M, Tannock IF. Factors associated with failure to publish large randomized trials presented at an oncology meeting. JAMA 2003; 290 (4): 495-501
46. Melander H, Ahlqvist-Rastad J, Meijer G, et al. Evidence b(i)ased medicine: selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. BMJ 2003; 326 (7400): 1171-3
47. Horton R. Vioxx, the implosion of Merck, and aftershocks at the FDA. Lancet 2004; 364 (9450): 1995-6
48. Papanikolaou PN, Churchill R, Wahlbeck K, et al. Safety reporting in randomized trials of mental health interventions. Am J Psychiatry 2004; 161 (9): 1692-7
49. Pirmohamed M, Darbyshire J. Collecting and sharing information about harms. BMJ 2004; 329 (7456): 6-7
50. De Angelis C, Drazen JM, Frizelle FA, et al. Clinical trial registration: a statement from the International Committee of Medical Journal Editors. Lancet 2004; 364 (9438): 911-2
51. Vandenbroucke JP. Balancing benefits and harms in health care: observational data on harm should complement systematic reviews of benefit [letter]. BMJ 2003; 327 (7417): 750